FDA’s Sentinel Program Readies For Patrol As Stakeholders Watch For Details
Executive Summary
HHS unveiled the first phase of FDA's "Sentinel" post-market drug safety surveillance initiative with fanfare May 22, but stakeholders will have to wait a while for details on funding and the timing of a full-scale rollout
You may also be interested in...
Romney Advisor Leavitt Champions Part D As Model For Medicare Reform
As the presumptive architect of Republican presidential candidate Mitt Romney’s transition plan, former HHS Secretary Mike Leavitt would be a strong proponent for modeling future Medicare Parts A and B reforms on the Part D program.
Sentinel Initiative Needs Better Defined Goals, Outside Review Concludes
The Pharmacovigilance Review Subcommittee of FDA's Science Board reports a lack of clarity within CDER over just what purpose the drug safety program is supposed to serve.
FDA's Science Board To Review Comparative Effectiveness, Pharmacovigilance, Nanotech
The May 20 meeting follows a recent reorganization of the safety functions in the Center for Drug Evaluation and Research.